Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study.

PURPOSE In randomized trials the combination of cisplatin and paclitaxel was superior to cisplatin and cyclophosphamide in advanced-stage epithelial ovarian cancer. Although in nonrandomized trials, carboplatin and paclitaxel was a less toxic and highly active combination regimen, there remained concern regarding its efficacy in patients with small-volume, resected, stage III disease. Thus, we conducted a noninferiority trial of cisplatin and paclitaxel versus carboplatin and paclitaxel in this population. PATIENTS AND METHODS Patients with advanced ovarian cancer and no residual mass greater than 1.0 cm after surgery were randomly assigned to receive cisplatin 75 mg/m2 plus a 24-hour infusion of paclitaxel 135 mg/m2 (arm I), or carboplatin area under the curve 7.5 intravenously plus paclitaxel 175 mg/m2 over 3 hours (arm II). RESULTS Seven hundred ninety-two eligible patients were enrolled onto the study. Prognostic factors were similar in the two treatment groups. Gastrointestinal, renal, and metabolic toxicity, as well as grade 4 leukopenia, were significantly more frequent in arm I. Grade 2 or greater thrombocytopenia was more common in arm II. Neurologic toxicity was similar in both regimens. Median progression-free survival and overall survival were 19.4 and 48.7 months, respectively, for arm I compared with 20.7 and 57.4 months, respectively, for arm II. The relative risk (RR) of progression for the carboplatin plus paclitaxel group was 0.88 (95% confidence interval [CI], 0.75 to 1.03) and the RR of death was 0.84 (95% CI, 0.70 to 1.02). CONCLUSION In patients with advanced ovarian cancer, a chemotherapy regimen consisting of carboplatin plus paclitaxel results in less toxicity, is easier to administer, and is not inferior, when compared with cisplatin plus paclitaxel.

[1]  M. Bookman Developmental chemotherapy in advanced ovarian cancer: incorporation of newer cytotoxic agents in a phase III randomized trial of the Gynecologic Oncology Group (GOG-0182). , 2002, Seminars in oncology.

[2]  H. V. van Houwelingen,et al.  Exploratory phase III study of paclitaxel and cisplatin versus paclitaxel and carboplatin in advanced ovarian cancer. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  M. Piccart,et al.  Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results. , 2000, Journal of the National Cancer Institute.

[4]  A. Adjei,et al.  Review of the comparative pharmacology and clinical activity of cisplatin and carboplatin. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  D. Alberts,et al.  Chemotherapy in advanced ovarian cancer: four systematic meta-analyses of individual patient data from 37 randomized trials. Advanced Ovarian Cancer Trialists' Group. , 1998, British Journal of Cancer.

[6]  M. Gore,et al.  Randomized trial of dose-intensity with single-agent carboplatin in patients with epithelial ovarian cancer. London Gynaecological Oncology Group. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  R. Ozols,et al.  Short-course intravenous prophylaxis for paclitaxel-related hypersensitivity reactions. , 1997, Annals of oncology : official journal of the European Society for Medical Oncology.

[8]  K. Nielsen,et al.  Dose-effect study of carboplatin in ovarian cancer: a Danish Ovarian Cancer Group study. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  R. Ozols,et al.  Carboplatin and paclitaxel in ovarian carcinoma: a phase I study of the Gynecologic Oncology Group. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  E. Partridge,et al.  Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer , 1996, New England Journal of Medicine.

[11]  J B Vermorken,et al.  European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  C. Lipschultz,et al.  Cytotoxic studies of paclitaxel (Taxol) in human tumour cell lines. , 1993, British Journal of Cancer.

[13]  W. Mcguire Taxol: a new drug with significant activity as a salvage therapy in advanced epithelial ovarian carcinoma. , 1993, Gynecologic oncology.

[14]  E. Eisenhauer,et al.  Carboplatin versus cisplatin , 1993 .

[15]  E Wiltshaw,et al.  Carboplatin dosage: prospective evaluation of a simple formula based on renal function. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  Roger W. Jelliffe,et al.  Creatinine Clearance: Bedside Estimate , 1973 .

[17]  W. Kruskal,et al.  Use of Ranks in One-Criterion Variance Analysis , 1952 .